Secondary offering and initial public offering of OXiGENE Inc. (US) — USD 29 million

Carnegie acted as adviser to OXiGENE Inc. in the secondary offering of shares to European investors and in the initial public offering on Stockholmsbörsen. OXiGENE Inc. is active in pharmaceutical development within cancer treatment, and publicly traded at Nasdaq (US). November, 1996.